Feds join probe into stolen Lilly drugs; Mylan, Takeda enter Actos settlement;

  @FiercePharma: Ex-Schering chiefs join up at Bausch. Report | Follow @FiercePharma

> Federal investigators will join police in Enfield, Connecticut today in trying to figure out who stole an estimated $50 million to $75 million in prescription drugs from an Eli Lilly warehouse. Story

> Mylan has entered into settlement agreements with Takeda Pharmaceutical related to two treatments for Type 2 diabetes: Actoplus Met, 15 mg/500 mg and 15 mg/850 mg and Actos, 15, 30 and 45 mg. Release

> A former Pfizer scientist who accuses the pharmaceutical giant of firing her in retaliation for pressing safety complaints actually lost her job for refusing to return to work, said company attorney William Anthony as a much-watched civil suit opened Monday in U.S. District Court. Story

> Bayer Schering Pharma Asia Pacific witnessed 13 percent sales growth, with sales reaching 1.04 billion euro in 2009, which makes Asia Pacific the fastest growing region for the German pharmaceutical company. Article

> Fresenius Kabi has opened a temperature controlled, high-bay, fully automated warehouse near its manufacturing plant in Austria, according to its partner on the project. Item

> GlaxoSmithKline (GSK) announced management changes related to its vaccines business as part of a planned succession strategy. With immediate effect Jean Stephenne is appointed chairman, GSK Biologicals. Mr. Stephenne will assume this role in addition to his existing position as president, GSK Biologicals. Report

> Hospitalization rates for heart patients taking warfarin, the world's most-prescribed blood thinner, dropped by approximately 30 percent when genetic information was available to doctors prescribing the drug. Release

> The results of a new Pharma Insight study released today by Wolters Kluwer Pharma Solutions is not exactly what the doctor ordered.  The company's annual analysis of the U.S. pharma market suggests that the economy has led to increased patient participation in decisions about prescription drugs.  What may be more striking, that rising influence often is at odds with a patient's physician. Release

Biotech News

  @FierceBiotech: Quintiles sheds CRO label. Report | Follow @FierceBiotech

 @JohnCFierce: Venture funding for life sciences $1.9B in 4Q, flat from the 3Q, says VentureDeal. But biotech VC rounds swell. Follow @JohnCFierce   

> Shares of BioTime shot up over 33 percent this morning after investors got a whiff of a newly published scientific paper in which the biotech company says it was able to reverse the aging process in cells. Article

> MannKind addresses Afrezza concerns following FDA response. Report

> Biotech VC funding leaps in 4Q as life sciences stays flat. Article

> Malvern, PA-based Promedior has lined up a fresh $12 million injection of venture cash to get its lead drug into mid-stage trials for inflammatory and fibrotic diseases. Article

> Lilly inks $335 million deal for underarm testosterone therapy. Story

Manufacturing News

> FDA's Sharfstein talks REMS, track and trace. Report

> Merck, GE and IBM collaborate on vaccine plant. Item

> Process remains the determining factor for whether single-use technology is a fit in a bioprocess operation, says Janice Abel, principal consultant at ARC Advisory Group. Story

Biotech Research News

> Scientists unlock poppy's painkilling genes. Article

> A stem cell expert and four top scientists in the genomics field are among the world's 'hottest' scientists, as selected by Thomson Reuters. Story

> Mice provide clues to regeneration. Item

> Hydra could be key in Alzheimer's studies. Report

And Finally... It took half a century, but a tiny drug maker on Long Island has finally found a potentially lucrative use for its only medicine: straightening clenched fingers. And, if research proves successful, treating a condition that causes bent penises. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.